In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 433-443

  Doroshyenko, Oxana ^a   Fuhr, Uwe ^a   Kunz, Daria ^a   Frank, Dorothee ^a   Kinzig, Martina ^b   Jetter, Alexander ^a,f   Reith, Yvonne ^a   Lazar, Andreas ^a   Taubert, Dirk ^a   Kirchheiner, Julia ^c   Baum, Matthias ^d   Eisenbrand, Gerhard ^d   Berger, Franz Ingo ^d   Bertow, Daniel ^d   Berkessel, Albrecht ^a   Sörgel, Fritz ^b,e   Schömig, Edgar ^a   Tomalik Scharte, Dorota ^a,g  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE; N ACETYL S(2 HYDROXY 2 CARBAMOYLETHYL) CYSTEINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; GENOTYPE; HUMAN; IN VIVO STUDY; PHENOTYPE; PRIORITY JOURNAL; TOXICOKINETICS; URINARY EXCRETION;

ACRYLAMIDE; CARCINOGENS; CHLORZOXAZONE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2E1; DISULFIRAM; ENZYME INHIBITORS; ETHANOL; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 60549099955     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0832     Document Type: Article

References (75)

1. Friedman MA. Chemistry, biochemistry, and safety of acrylamide. J Agric Food Chem 2003;51:4504-26.
2. Mucci LA, Wilson KM. Acrylamide intake through diet and human cancer risk. J Agric Food Chem 2008;56:6013-9.
3. Klaunig JE. Acrylamide carcinogenicity. J Agric Food Chem 2008;56:5984-8.
4. Hazardous Substances Databank [database on the Internet]. Bethesda (MD): National Library of Medicine (U.S.). c1999 [updated 2008 Jun 12; cited 2008 Jul 12]. Available from: http://toxnet.nlm.nih.gov/cgibin/sis/htmlgen?HSDB.
5. IARC. Monographs on the evaluation of carcinogenic risks to humans. Vol. 60. Some industrial chemicals. Lyon: IARC; 1994. p. 389-433.
6. Dybing E, Farmer PB, Andersen M, et al. Human exposure and internal dose assessments of acrylamide in food. Food Chem Toxicol 2005;43:365-410.
7. World Health Organization. Health implications of acrylamide in food. Joint FAO/WHO consultation, Geneva, Switzerland, June 2002. Available from: http://www.who.int/foodsafety/publications/chem/acrylamide-june2002/en/.
8. Sörgel F, Weissenbacher R, Kinzig-Schippers M, et al. Acrylamide: increased concentrations in homemade food and first evidence of its variable absorption from food, variable metabolism and placental and breast milk transfer in humans. Chemotherapy 2002;48:267-74.
9. Fuhr U, Boettcher MI, Kinzig-Schippers M, et al. Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity. Cancer Epidemiol Biomarkers Prev 2006;15:266-71.
10. Fennell TR, Sumner SC, Snyder RW, et al. Metabolism and hemoglobin adduct formation of acrylamide in humans. Toxicol Sci 2005;85:447-59.
11. Boettcher MI, Bolt HM, Drexler H, Angerer J. Excretion of mercapturic acids of acrylamide and glycidamide in human urine after single oral administration of deuterium-labelled acrylamide. Arch Toxicol 2006;80:55-61.
12. Fennell TR, Sumner SC, Snyder RW, Burgess J, Friedman MA. Kinetics of elimination of urinary metabolites of acrylamide in humans. Toxicol Sci 2006;93:256-67.
13. Shipp A, Lawrence G, Gentry R, et al. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects. Crit Rev Toxicol 2006;36:481-608.
14. Schettgen T, Kütting B, Hornig M, et al. Trans-placental exposure of neonates to acrylamide-a pilot study. Int Arch Occup Environ Health 2004;77:213-6.
15. Barber DS, Hunt JR, Ehrich MF, Lehning EJ, LoPachin RM. Metabolism, toxicokinetics and haemoglobin adduct formation in rats following subacute and subchronic acrylamide dosing. Neurotoxicology 2001;22:341-53.
16. Tareke E, Twaddle NC, McDaniel LP, Churchwell MI, Young JF, Doerge DR. Relationships between biomarkers of exposure and toxicokinetics in Fischer 344 rats and B6C3F1 mice administered single doses of acrylamide and glycidamide and multiple doses of acrylamide. Toxicol Appl Pharmacol 2006;217:63-75.
17. Puppel N, Tjaden Z, Fueller F, Marko D. DNA strand breaking capacity of acrylamide and glycidamide in mammalian cells. Mutat Res 2005;580:71-80.
18. Kurebayashi H, Ohno Y. Metabolism of acrylamide to glycidamide and their cytotoxicity in isolated rat hepatocytes: protective effects of GSH precursors. Arch Toxicol 2006;80:820-8.
19. Sumner SC, Fennell TR, Moore TA, Chanas B, Gonzalez F, Ghanayem BI. Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem Res Toxicol 1999;12: 1110-6.
20. Ghanayem BI, Hamilton LP, Churchwell MI, et al. Role of CYP2E1 in the epoxidation of acrylamide to glycidamide and formation of DNA and haemoglobin adducts. Toxicol Sci 2005;88:311-8.
21. Settels E, Bernauer U, Palavinskas R, Klaffke HS, Gundert-Remy U, Appel KE. Human CYP2E1 mediates the formation of glycidamide from acrylamide. Arch Toxicol 2008;82:717-27.
22. Boettcher MI, Schettgen T, Kutting B, Pischetsrieder M, Angerer J. Mercapturic acids of acrylamide and glycidamide as biomarkers of the internal exposure to acrylamide in the general population. Mutat Res 2005;580:167-76.
23. Bjellaas T, Stolen LH, Haugen M, et al. Urinary acrylamide metabolites as biomarkers for short-term dietary exposure to acrylamide. Food Chem Toxicol 2007;45:1020-6.
24. Boettcher MI, Angerer J. Determination of the major mercapturic acids of acrylamide and glycidamide in human urine by LC-ESI- MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2005;824: 283-94.
25. Kjuus H, Hansteen IL, Ryberg D, Goffeng LO, Ovrebø S, Skaug V. Chromosome aberrations in tunnel workers exposed to acrylamide and N-methylolacrylamide. Scand J Work Environ Health 2005;31:300-6.
26. Hasegawa K, Miwa S, Isomura K, Tsutsumiuchi K, Taniguchi H, Miwa J. Acrylamide-responsive genes in the nematode Caenorhabditis elegans. Toxicol Sci 2008;101:215-25.
27. Schettgen T, Rossbach B, Kütting B, Letzel S, Drexler H, Angerer J. Determination of haemoglobin adducts of acrylamide and glycidamide in smoking and non-smoking persons of the general population. Int J Hyg Environ Health 2004;207:531-9.
28. Doerge DR, da Costa GG, McDaniel LP, Churchwell MI, Twaddle NC, Beland FA. DNA adducts derived from administration of acrylamide and glycidamide to mice and rats. Mutat Res 2005;580:131-41.
29. Tyla RW, Friedman MA, Losco PE, et al. Rat two-generation reproduction and dominant lethal study of acrylamide in drinking water. Reprod Toxicol 2000;14:385-401.
30. Hogervorst JG, Schouten LJJ, Konings EJ, Goldbohm RA, van den Brandt PA. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2304-13.
31. Hogervorst JG, Schouten LJ, Konings EJ, Goldbohm RA, van den Brandt PA. Dietary acrylamide intake and the risk of renal cell, bladder, and prostate cancer. Am J Clin Nutr 2008;87:1428-38.
32. Olesen PT, Olsen A, Frandsen H, Frederiksen K, Overvad K, Tjønneland A. Acrylamide exposure and incidence of breast cancer among postmenopausal women in the Danish Diet, Cancer and Health Study. Int J Cancer 2008;122:2094-100.
33. Ghanayem BI, Witt KL, Kissling GE, Tice RR, Recio L. Absence of acrylamide-induced genotoxicity in CYP2E1-null mice: evidence consistent with a glycidamide-mediated effect. Mutat Res 2005;578:284-97.
34. Diletti E, Hauschke D, Steinijans VW. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int J Clin Pharmacol Ther Toxicol 1992;30:59-62.
35. Taubert D, Harlfinger S, Henkes L, Berkels R, Schomig E. Influence of processing parameters on acrylamide formation during frying of potatoes. J Agric Food Chem 2004;52:2735-9.
36. Urban M, Kavvadias D, Riedel K, Scherer G, Tricker AR. Urinary mercapturic acids and a hemoglobin adduct for the dosimetry of acrylamide exposure in smokers and nonsmokers. Inhal Toxicol 2006;18:831 -9.
37. Bergmark E, Calleman CJ, He F, Costa LG. Determination of hemoglobin adducts in humans occupationally exposed to acrylamide. Toxicol Appl Pharmacol 1993;120:45-54.
38. Bergmark E. Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and nonsmokers. Chem Res Toxicol 1997;10:78-84.
39. Paulsson B, Athanassiadis I, Rydberg P, Tornqvist M. Hemoglobin adducts from glycidamide: acetonization of hydrophilic groups for reproducible gas chromatography/tandem mass spectrometric analysis. Rapid Commun Mass Spectrom 2003;17:1859-65.
40. Bergmark E, Calleman CJ, Costa LG. Formation of hemoglobin adducts of acrylamide and its epoxide metabolite glycidamide in the rat. Toxicol Appl Pharmacol 1991;111:352-63.
41. Tornqvist M. Epoxide adducts to N-terminal valine of hemoglobin. Methods Enzymol 1994;231:650-7.
42. Rydberg P, Lüning B, Wachtmeister CA, Törnqvist M. Synthesis and characterization of N-substituted valines and their phenyl-and pentafluorophenyl-thiohydantoins. Acta Chem Scand 1993;47:813-7.
43. Lucas D, Berthou F, Girre C, Poitrenaud F, Ménez JF. High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 activity in humans. J Chromatogr 1993;622:79-86.
44. Farker K, Lehmann MH, Oelschlägel B, et al. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp Toxicol Pathol 1998;50:425-31.
45. Watanabe J, Hayashi S-i, Nakachi K, et al. Pst and Rsa I RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 1990;18:7194.
46. Ko Y, Koch B, Harth V, et al. Rapid analysis of GSTM1, GSTT1 and GSTP1 polymorphisms using real-time polymerase chain reaction. Pharmacogenetics 2000;10:271-4.
47. Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1,P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 1998;7:1013-8.
48. Berkessel A, Sklorz CA. Mn-trimethyltriazacyclononane/ascorbic acid: a remarkably efficient catalyst for the epoxidation of olefins and the oxidation of alcohols with hydrogen peroxide. Tetrahedron Lett 1999;40:7965-8.
49. Sörgel F, Kinzig-Schippers M, Berkessel A, Schröder M, Koch C. Analysis of acrylamide and glycidamide in biological samples. Anaheim (CA): Abstracts of Papers, 227th ACS National Meeting; 2004 March 28-April 1. AGFD 78.
50. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998;38:82-9.
51. Ernstgård L, Warholm M, Johanson G. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br J Clin Pharmacol 2004;58:190-200.
52. Steinijans VW, Neuhauser M, Bretz F. Equivalence concepts in clinical trials. Eur J Drug Metab Pharmacokinet 2000;25:38-40.
53. Emery MG, Jubert C, Thummel KE, Kharasch ED. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J Pharmacol Exp Ther 1999;291:213-9.
54. Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and Nacetyltransferase in healthy human subjects. Br J Clin Pharmacol 2002;53:155-62.
55. Deitrich RA, Erwin VG. Mechanism of the inhibition of aldehyde dehydrogenase in vivo by disulfiram and diethyldithiocarbamate. Mol Pharmacol 1971;7:301-7.
56. Loo TW, Bartlett MC, Clarke DM. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharm 2004;1:426-33.
57. Musacchio JM, Goldstein M, Anagnoste B, Poch G, Kopin IJ. Inhibition of dopamine-β-hydroxylase by disulfiram in vivo. J Pharmacol Exp Ther 1966;152:56-61.
58. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006;66:10425-33.
59. Oneta CM, Lieber CS, Li J, Rüttimann S, Schmid B, Lattmann J, Rosman AS, Seitz HK. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J Hepatol 2002;36:47-52.
60. Hartmann EC, Boettcher MI, Schettgen T, Fromme H, Drexler H, Angerer J. Hemoglobin adducts and mercapturic acid excretion of acrylamide and glycidamide in one study population. J Agric Food Chem 2008;56:6061-8.
61. Scherer G, Engl J, Urban M, Gilch G, Janket D, Riedel K. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2007;47:171-83.
62. Vesper HW, Ospina M, Meyers T, Ingham L, Smith A, Gray JG, Myers GL. Automated method for measuring globin adducts of acrylamide and glycidamide at optimized Edman reaction conditions. Rapid Commun Mass Spectrom 2006;20:959-64.
63. XieQ,SunH,LiuY,DingX,FuD,LiuK.Adductionof biomacromolecules with acrylamide (AA) in mice at environmental dose levels studied by accelerator mass spectrometry. Toxicol Lett 2006;163:101-8.
64. Haufroid V, Buchet JP, Gardinal S, Lison D. Cytochrome P4502E1 phenotyping by the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. Int Arch Occup Environ Health 2002;75:453-8.
65. Kim RB, O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995;57:645-55.
66. Kim RB, Yamazaki H, Chiba K, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996;279:4-11.
67. Kato S, Shields PG, Caporaso NE, et al. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev 1994;3:515-8.
68. Lucas D, Ménez C, Floch F, et al. Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic Caucasians. Alcohol Clin Exp Res 1996;20:1033-7.
69. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Polymorphisms at the glutathione-S-transferase GSTM1, GSTT1 and GSTP1 loci; risk of ovarian cancer by histologigal subtype. Carcinogenesis 2001;22:67-72.
70. Rossini A, Rapozo D, Amorim L, et al. Frequencies of GSTM1, GSTT1, and GSTP1 polymorphisms in a Brazilian population. Genet Mol Res 2002;1:233-40.
71. Watson MA, Stewart RK, Smith GBJ, Massey TE, Bell DA. Human glutathione S-transferase PI polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis (Lond) 1998;19:275-80.
72. Sprenger R, Schlagenhaufer R, Kerb R, et al. Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics 2000;10:557-65.
73. Welfare M, Monesola acrylamide, Bassendine MF, Daly AK. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999;8:289-92.
74. Zhong S, Howie AF, Ketterer B, et al. Glutathione 5-transferase p locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991;12:1533-7.
75. Paulsson B, Rannug A, Henderson AP, Golding BT, Törnqvist M, Warholm M. In vitro studies of the influence of glutathione transferases and epoxide hydrolase on the detoxification of acrylamide and glycidamide in blood. Mutat Res 2005;580:53-9.